Abstract

Natriuretic peptides (NPs) are cardio-derived hormones that have a crucial role in maintaining cardiovascular homeostasis. Physiological effects of NPs are mediated by binding to natriuretic peptide receptors 1 and 2 (NPR1/2), whereas natriuretic peptide receptor 3 (NPR3) acts as a clearance receptor that removes NPs from the circulation. Mouse studies have shown that local NP-signaling in the kidney glomerulus is important for the maintenance of renal homeostasis. In this study we examined the expression of NPR3 in kidney tissue and explored its involvement in renal physiology and disease by generating podocyte-specific knockout mice (NPR3podKO) as well as by using an NPR3 inhibitor (NPR3i) in rodent models of kidney disease. NPR3 was highly expressed by podocytes. NPR3podKO animals showed no renal abnormalities under healthy conditions and responded similarly to nephrotoxic serum (NTS) induced glomerular injury. However, NPR3i showed reno-protective effects in the NTS-induced model evidenced by decreased glomerulosclerosis and reduced podocyte loss. In a ZSF1 rat model of diabetic kidney injury, therapy alone with NPR3i did not have beneficial effects on renal function/histology, but when combined with losartan (angiotensin receptor blocker), NPR3i potentiated its ameliorative effects on albuminuria. In conclusion, these results suggest that NPR3 may contribute to kidney disease progression.

Details

Title
Unraveling the role of natriuretic peptide clearance receptor (NPR3) in glomerular diseases
Author
Dabaghie, Dina 1 ; Charrin, Emmanuelle 1 ; Tonelius, Pernilla 2 ; Rosengren, Birgitta 2 ; Korkut, Gizem 1 ; Granqvist, Anna B. 2 ; Lal, Mark 2 ; Patrakka, Jaakko 3 

 Karolinska Institutet, Division of Pathology, Department of Laboratory Medicine, Huddinge, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626) 
 AstraZeneca, Bioscience Renal, Cardiovascular, Renal and Metabolism (CVRM), R&D Biopharmaceuticals, Gothenburg, Sweden (GRID:grid.418151.8) (ISNI:0000 0001 1519 6403) 
 Karolinska Institutet, Division of Pathology, Department of Laboratory Medicine, Huddinge, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Unilabs, Department of Pathology, Stockholm, Sweden (GRID:grid.4714.6) 
Pages
11850
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3059132201
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.